<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41731">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563106</url>
  </required_header>
  <id_info>
    <org_study_id>SB-2-004-005</org_study_id>
    <nct_id>NCT02563106</nct_id>
  </id_info>
  <brief_title>A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of C.Diff in Patients With a Diagnosis of a Lower Respiratory Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synthetic Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synthetic Biologics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2b Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004
      Compared to Placebo for the Prevention of Clostridium difficile Infection (CDI) in
      Hospitalized Patients receiving IV ceftriaxone with a Diagnosis of a Lower Respiratory Tract
      Infection (LRTI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b, randomized, double-blind, placebo controlled, parallel-group,
      multi-center proof-of-concept study to assess the potential of SYN-004 in the prevention of
      CDI and the unwanted side effects of IV antibiotic treatment in at risk patients who are
      hospitalized for LRTI and receiving IV ceftriaxone alone or in combination with a macrolide.
      Subjects will be 50 years or older. The entire duration of the study may be up to 59 days.
      All patients will be evaluated for the occurrence of CDI and AAD by testing according to
      local diagnostic standards and monitoring for diarrhea (3 or more unformed stools per 24
      hour period).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with CDAD</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">413</enrollment>
  <condition>Clostridium Difficile</condition>
  <condition>Clostridium Infections</condition>
  <arm_group>
    <arm_group_label>SYN-004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYN-004 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYN-004</intervention_name>
    <arm_group_label>SYN-004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Expected minimum hospital stay of 5 days

          -  Expected â‰¥5 day course of intravenous (IV) ceftriaxone alone or in combination with a
             macrolide

          -  Clinical diagnosis of moderate to severe lower respiratory tract infection consisting
             of signs and symptoms of a lower respiratory tract infection and Pneumonia Severity
             Index (PSI/PORT) score for CAP of 90-130, inclusive. Evidence of a new or progressive
             infiltrate on chest x-ray is recommended.

        Exclusion Criteria:

          -  Presence of a diarrheal illness within 72 hours prior to randomization

          -  Current treatment for CDAD or ongoing active CDI, as evidenced by clinical signs of
             diarrhea along with the presence of toxin A and/or B (or their respective genes, tcdA
             and/or tcdB) of C. difficile in the stool

          -  Number of previous CDAD episodes &gt;1 within 12 weeks of randomization and no C.
             difficile infection (CDI) within 4 weeks of randomization

          -  Use of antibiotics within 1 month of start of study drug except for the current
             illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Gottlieb, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Synthetic Biologics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Natchitoches</city>
        <state>Louisiana</state>
        <zip>71457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 10, 2016</lastchanged_date>
  <firstreceived_date>September 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
